Opinion|Videos|September 11, 2024
Central Precocious Puberty Treatment Starts, Discontinuations and Misconceptions
Experts address common misconceptions about the timing of central precocious puberty treatment initiation and discontinuation, highlighting research on outcomes for therapy started before age 7 and continued beyond age 12.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are common misconceptions regarding the timing of therapy initiation and discontinuation?
- What has research shown regarding outcomes for initiating therapy before age 7 years or discontinuing therapy after age 12 years?
- What consideration should clinicians give about the time to first menses after treatment cessation?
Advertisement
Related to this article
Researchers discuss how testosterone changes during early puberty may influence depression and anxiety symptoms in girls and implications for pediatricians.
The FDA approved insulin icodec-abae for children 10+ with T2D, based on adult ONWARDS data and a single-dose pediatric pharmacokinetic study.
In a meta-analysis of 46 RCTs, behavioral interventions modestly improved HbA1c in youth with T1D; family-focused approaches worked best.
Nationwide Children's experts urge early screening and family-based lifestyle change as youth-onset T2D progresses faster than adult disease.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Skipping newborn vitamin K tied to 47% higher infant bleeding risk
2
Contemporary Pediatrics week in review: November 2-6, 2026
3
Study identifies gaps in infant RSV immunization timing
4
Breastfeeding essentials: Assessing latch and milk transfer
5